Co-Enzyme Q10
Phase 3Small molecule
Co-Enzyme Q10 is one of 16 small molecule programs targeting Ovarian Reserve. It is currently in Phase 3.
1
Indications
3
Total Trials
2
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
23 competitors in Ovarian Reserve
#DrugCompanyPhaseTrials
1Myoinositol
SSohag University
Phase 3
Co-Enzyme Q10
TTanta University
Phase 3
Thalomid
Bristol-Myers SquibbPreclinical
Remicade
Johnson & JohnsonPreclinical
Trexall
Jazz PharmaceuticalsPreclinical
Danocrine
SanofiPreclinical
Zoladex
TTerSera Therapeutics LLC
Preclinical
Growth Hormone
PfizerPreclinical
Recombinant LH
UUniversity of Colorado, Denver
Phase 2
Cetrotide
EMD SeronoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ovarian Reserve1 trial
of Myo-inositol, Melatonin and Co-enzyme q10 on Ovarian Reserve
Not yet recruiting·—·Phase 3·NCT06405204·200 enrolled
Sepsis1 trial
Effect of Montelukast Versus Co Enzyme in Sepsis
Completed·—·Phase 2/3·NCT05293132·90 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Co-Enzyme Q10. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTanta University